drugset
drugset / Trial / NCT07186387

Study of LW402 in Moderate-to-Severe Atopic Dermatitis

NCT07186387 ↗

Phase 2 Completed 144 enrolled Shanghai Longwood Biopharmaceuticals Co., Ltd.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a multi-center, randomized, double blind, placebo-controlled phase 2 study to evaluate the efficacy, safety, PK and PD ofLW402 in patients with moderate-to-severe atopic dermatitis.

Timeline

Start
2023-05-11
Primary completion
2024-09-25
Completion
2025-02-13

Drugs

EvaluationDrugModalityDoseRoute
Subject LW402 Unknown — Oral

Indications

atopic eczema